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Purpose: This study prospectively assessed the performance of liver stiffness measurements 
using point shear-wave elastography (p-SWE) in comparison with transient elastography (TE) in 
patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). 
Methods: Fifty-six consecutive adult patients with a histological diagnosis of NAFLD prospectively 
underwent TE and p-SWE on the same day. The median of 10 measurements (SWE-10), the first 
five (SWE-5), and the first three (SWE-3) measurements were analyzed for p-SWE. Liver biopsy 
was considered as the reference standard for liver fibrosis grade. Receiver operating characteristic 
(ROC) curves and areas under the ROC curves (AUROCs) were calculated to assess the performance 
of TE and p-SWE for the diagnosis of significant (F2-F4) and advanced fibrosis (F3-F4).
Results: Forty-six patients (27 men, 19 women; mean age, 54.7±9.1 years) had valid p-SWE and 
TE measurements. Twenty-seven patients (58.7%) had significant fibrosis and 18 (39.1%) had 
advanced fibrosis. For significant fibrosis, both SWE-10 (AUROC, 0.787; P=0.002) and SWE-
5 (AUROC, 0.809; P=0.001) provided higher diagnostic performance than TE (AUROC, 0.719; 
P=0.016) and SWE-3 (AUROC, 0.714; P=0.021), albeit without statistical significance (P=0.301). 
For advanced fibrosis, SWE-5 showed higher diagnostic performance (AUROC, 0.809; P<0.001) 
than TE (AUROC, 0.799; P<0.001), SWE-10 (AUROC, 0.797; P<0.001), and SWE-3 (AUROC, 
0.736; P=0.003), although the differences were not statistically significant (P=0.496). The 
optimal SWE-10 and SWE-5 cutoff values were ≥8.4 and ≥7.8 for significant fibrosis, and ≥9.1 
and ≥8.8 for advanced fibrosis, respectively.
Conclusion: TE and p-SWE showed similar performance for the diagnosis of significant and 
advanced fibrosis in NAFLD patients.
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Introduction
Diffuse liver diseases have recently received increasing consideration 
due to their mounting incidence, with particular attention to hepatic 
steatosis [1], which is related to two main clinical-pathological 
entities: alcoholic fatty liver disease and nonalcoholic fatty liver 
disease (NAFLD). NAFLD affects approximately 90% of the obese 
population, as well as 15%-40% of the general population. NAFLD 
can result in a multistep progressive disease, potentially evolving 
into nonalcoholic steatohepatitis (NASH), advanced fibrosis (in 
approximately 25% of cases), cirrhosis (10%-20% of cases), and 
hepatocellular carcinoma (4% of cases) [2-4]. In NAFLD patients, 
the most important clinical end-points are the differentiation 
of NASH from simple hepatic steatosis and the identification of 
advanced fibrosis. Considering the increased risk of liver failure 
and hepatocellular carcinoma in patients with cirrhosis, it is of 
the utmost relevance to follow-up fibrosis evolution noninvasively 
in order to establish an appropriate treatment and avoid disease 
progression [5].
The reference standard for the diagnosis of hepatic fibrosis is 
liver biopsy, an invasive procedure with known complications that 
is prone to sampling errors, intra- and inter-observer variability, 
and limited repeatability. Among the various noninvasive methods 
as alternative tools for staging hepatic fibrosis, the currently most-
used technique in clinical practice is transient elastography (TE; 
FibroScan, Echosens, Paris, France). However, this technique has 
some limitations, such as obesity (which was partially overcome by 
the introduction of a new XL probe), narrow intercostal spaces, and 
the presence of ascites. When using the conventional M probe, in 
patients with steatosis of >66% at liver biopsy, TE provides a higher 
false-positive rate in terms of liver stiffness (LS) measurements. 
Therefore, TE (using the M probe) may overestimate liver fibrosis 
in patients with a body mass index (BMI) >30 kg/m2 and severe 
steatosis [6].
Point shear-wave elastography (p-SWE) may represent an 
alternative to TE. SWE is integrated into conventional ultrasound 
equipment, enabling a rapid quantitative evaluation of LS [7]. SWE 
allows the operator to precisely visualize where the measurements 
are performed on B-mode ultrasound images, even in presence of 
ascites [8]. Preliminary results have shown high accuracy of p-SWE 
for the assessment of liver fibrosis in patients affected by chronic 
viral hepatitis [9-11], but few data are available regarding the 
comparison between p-SWE and TE, especially in patients with 
NAFLD [12,13] and to our knowledge, no prior study has assessed 
NAFLD using an RS80A ultrasound system. Therefore, in the last 
version of the European Federation of Societies for Ultrasound in 
Medicine and Biology (EFSUMB) guidelines on the clinical use of 
liver ultrasound elastography, recommendations are still lacking on 
the preferred first-line method for the assessment of hepatic fibrosis 
in patients with NAFLD [14]. 
The aim of our study was to prospectively assess the accuracy of 
p-SWE for the quantitative evaluation of LS in patients with NAFLD, 
in comparison with TE and liver biopsy, and to determine the optimal 
cutoff values for significant and advanced fibrosis.
Materials and Methods
This prospective study was approved by the Ethics Committee of 
University Hospital, a tertiary center for the treatment of chronic liver 
disease (Palermo 1 ID-2014). All subjects provided written informed 
consent for this study in accordance with the Declaration of Helsinki.
Population
Between March 2017 and November 2018, 56 consecutive adult 
patients with a histological diagnosis of NAFLD prospectively 
underwent TE (FibroScan, Echosens) and p-SWE (RS80A ultrasound 
system, Samsung Medison, Seoul, Korea) on the same day. The 
following exclusion criteria were considered: (1) a history of 
significant alcohol consumption (>21 standard drinks per week in 
men or >14 standard drinks per week in women) or virus-related 
chronic hepatitis; (2) a history of taking drugs that may cause 
steatosis, obstructive cholestasis, acute hepatitis, and infiltrative 
liver diseases, which may affect the reliability of LS measurements; 
(3) liver inflammation, as indicated by aspartate transaminase 
(AST) and/or alanine transaminase (ALT) elevation >5 times the 
normal limits. In addition, after performing p-SWE, 10 (17.8%) 
patients were excluded due to failure of more than 75% of the 
SWE measurements considering a qualitative numeric index (the 
Reliability Measurement Index [RMI]) automatically calculated by 
the SWE software and shown on the ultrasonography (US) device 
screen. 
The same day of TE and p-SWE examinations, laboratory markers 
including ALT (IU/L), AST (IU/L), total cholesterol (mg/dL), and 
triglycerides (mg/dL), as well as BMI (kg/m2), were collected.
Imaging Techniques
All patients underwent TE performed with the FibroScan (Echosens) 
using the M or XL probe (46 and 10 patients, respectively). LS was 
assessed after at least 4 hours of fasting by a trained operator with 
more than 15 years of experience who had previously performed at 
least 300 examinations in patients with chronic liver disease. The 
probe was positioned at the level of the right liver lobe through 
the intercostal spaces with patients in the supine position with 
the right arm in maximum abduction. TE displayed the region of 
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interest (ROI) in ultrasound A-mode and measured LS in a volume 
represented by a cylinder 1 cm wide and 4 cm long located between 
25 mm and 65 mm below the skin surface. Uncorrected acquisitions 
are automatically ruled out from the US software. The results were 
expressed in kilopascals (kPa) and ranged from 2.5 to 75 kPa.
The most important parameter for assessing the reliability of 
TE evaluation is the interquartile range (IQR), which reflects the 
variability of the validated measures, and should not exceed 20%-
30% of the median value. All LS measurements were classified 
into three reliability categories: (1) very reliable (IQR/M ≤0.10); (2) 
reliable (0.10<IQR/M≤0.30, or IQR/M >0.30 with LS median <7.1 
kPa); or (3) poorly reliable (IQR/M >0.30 with LS median ≥7.1 kPa). 
Only patients with 10 valid measurements were included, and poorly 
reliable results were excluded from the analysis, without being 
further enrolled for SWE [15].
All p-SWE examinations were performed by one radiologist, 
blinded to biopsy and laboratory results, using an ultrasound 
machine (Samsung RS80A, Samsung Medison Co.) equipped 
with p-SWE software on a convex broadband probe (CA1-7A). 
All patients fasted for a minimum of 2 hours and rested for a 
minimum of 10 minutes before undergoing p-SWE evaluation. 
During the LS measurements, the probe was positioned on the 
right liver lobe, through the intercostal spaces with the patient 
lying in supine position with the right arm in maximal abduction. LS 
measurements were obtained as median values in kilopascals (kPa) 
from a rectangular ROI placed between 2 cm from the liver capsule 
and at a maximum depth of up to 5 cm beneath the skin in the 
hepatic parenchyma, carefully avoiding large intrahepatic vessels 
and biliary structures, and positioning the focus at the level of the 
ROI. During the LS measurements, patients were asked to stop 
breathing without a deep inspiration. For each measurement, the 
US equipment provided the RMI as an indicator of the calculated 
stiffness reliability, with a maximum value of 1. The US manufacturer 
developed this performance index through phantom and in vivo 
studies, since elastography data are often impaired by low signal-
to-noise ratio, making the results unreliable. It is obtained by 
the weighted sum of the residual of the wave equation and the 
magnitude of the shear wave. Pre-established RMI cutoff values are 
highly correlated with reproducible measurements and can be utilized 
to rule out unreliable measurements, thereby improving shear wave 
elastography performance [16]. Only measurements with an RMI 
≥0.6 and IQR/M ratios ≤30% were considered acceptable. Ten 
consecutive reliable measurements expressed in kPa were acquired 
in this study.
Reference Standard 
Liver biopsy was considered as the reference standard and was 
performed in all patients within 1 month in order to confirm the 
final diagnosis of NAFLD/NASH and to grade liver fibrosis. All biopsy 
specimens were evaluated by a single experienced pathologist, who 
was blinded to the patients' clinical and LS results. Hepatic fibrosis 
was graded according to the Kleiner score for NAFLD, as follows: 
F0, absence of fibrosis; F1, perisinusoidal or periportal fibrosis; F2, 
perisinusoidal and portal/periportal fibrosis; F3, septal or bridging 
fibrosis; and F4, cirrhosis [17]. The NAFLD activity score (NAS), grade 
of steatosis (0-3), lobular inflammation (0-3), and hepatocyte 
ballooning (0-2) were also recorded for each patient [18]. For the 
purposes of this study, grades F2-F4 were defined as significant 
fibrosis, while grades F3-F4 were defined as advanced fibrosis.
Statistical Analysis
The statistical analysis was performed by an expert statistician, 
in order to (1) compare patients with valid and failed p-SWE; (2) 
assess differences in diagnostic performances using p-SWE with 10 
measurements (SWE-10), the first five (SWE-5), and the first three 
(SWE-3) LS measurements; (3) calculate optimal TE and p-SWE 
cutoffs for the diagnosis of significant (F2-F3) and advanced (F3-
F4) fibrosis; and (4) correlate TE and p-SWE measurements with 
histopathological and laboratory markers. 
Continuous variables were expressed as mean and standard 
deviation. Categorical variables were expressed as numbers and 
percentages. Continuous variables were compared using analysis 
of variance and the independent t test, while categorical variables 
were compared using the chi-square test. Receiver operating 
characteristic (ROC) curves with 95% confidence intervals (CIs) and 
areas under the ROC curve (AUROCs with 95% CIs) were calculated 
to assess the diagnostic performance of successful TE and p-SWE 
measurements for the diagnosis of significant and advanced fibrosis. 
AUROCs for TE and p-SWE were compared using the DeLong test. 
Optimal cutoff values based on the Youden index of sensitivity 
and specificity, as well as alternative cutoffs for sensitivity ≥90% 
and specificity ≥90% were calculated. The correlations between 
TE, p-SWE, fibrosis, histopathological features of NASH (i.e., NAS, 
steatosis, inflammation, and ballooning), and laboratory markers (i.e., 
total cholesterol, triglycerides, AST, and ALT) was evaluated using the 
Spearman rank correlation coefficient (Spearman rho).
The statistical significance level was set at P<0.05, except for 
the Spearman rho, for which it was set at P<0.01 due to multiple 
comparisons. The statistical analysis was conducted using SPSS 
software version 20.0 (IBM Corp., Armonk, NY, USA).
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(19.6%), F3 in five cases (10.9%), and F4 in the remaining 13 cases 
(28.2%). Overall, significant fibrosis (F2-F4) was present in 27 
patients (58.7%), while advanced fibrosis (F3-F4) was observed in 
18 patients (39.1%).
None of the patients had poorly reliable TE evaluations, whereas 
10 (17.8%) subjects were excluded from the initial population 
due to failure of more than 75% of the SWE measurements. The 
excluded subjects had advanced (F3-F4) or significant (F2) fibrosis 
in nine cases (90.0%) and one case (10.0%), respectively. Compared 
to patients with successful p-SWE LS measurements, those with 
failed p-SWE measurements more frequently had advanced fibrosis 
(P=0.006), as well as having a higher BMI (mean, 33.7±4.9 kg/m2; 
P=0.011), and higher TE LS measurements (mean, 28.9±25.4 kPa; 
P<0.001).
Diagnostic Performance of TE and SWE
The diagnostic performance of TE and SWE is presented in Table 2. 
For the diagnosis of significant fibrosis, both SWE-10 (AUROC, 0.787; 
95% CI, 0.646 to 0.927; P=0.002) and SWE-5 (AUROC, 0.809; 
95% CI, 0.676 to 0.942; P=0.001) provided higher diagnostic 
performance than TE (AUROC, 0.719; 95% CI, 0.572 to 0.867; 
P=0.016) and SWE-3 (AUROC, 0.714; 95% CI, 0.560 to 0.869; 
P=0.021), although the differences among AUROC curves were not 
statistically significant (P=0.301) (Figs. 1, 2). 
For the diagnosis of advanced fibrosis, SWE-5 showed a higher 
diagnostic performance (AUROC, 0.809; 95% CI, 0.684 to 0.933; 
Results
Population Characteristics
The demographic and histopathological characteristics in the study 
population are summarized in Table 1. The final study population 
included 46 patients (27 men, 19 women; mean age, 54.7±9.1 
years; range, 40 to 73 years) with NAFLD. Patients' BMI ranged 
from 21.2 to 40.4 kg/m2 (mean value, 29.4±4.5 kg/m2). Diabetes 
was present in 18 patients (39.1%), whereas four patients (8.7%) 
had impaired fasting glycemia. Eleven patients (23.9%) presented 
cholesterol >200 mg/dL and six patients (13.0%) had triglyceride 
levels >175 mg/dL.
Through percutaneous liver biopsy, hepatic fibrosis was graded 
as F0 in four cases (8.7%), F1 in 15 cases (32.6%), F2 in nine cases 








Male 27 (58.7) 16 (40.7) 10 (55.6)
Female 19 (41.3) 11 (59.3) 8 (44.4)
Age (year) 54.7±9.1 57.9±9.0 58.8±8.2
BMI (kg/m2) 29.4±4.5 29.8±5.1 30.0±4.9
Fibrosis
F0 4 (8.7) 0 0
F1 15 (32.6) 0 0
F2 9 (19.6) 9 (33.3) 0
F3 5 (10.9) 5 (18.5) 5 (27.8)
F4 13 (28.2) 13 (48.2) 13 (72.2)
NAS 4.3±1.5 4.6±1.6 4.3±1.6
Steatosis grade
0 (<5%) 1 (2.2) 1 (3.7) 1 (5.6)
1 (5%-33%) 14 (30.4) 8 (29.7) 7 (38.9)
2 (33%-66%) 17 (37.0) 9 (33.3) 4 (22.2)
3 (>66%) 14 (30.4) 9 (33.3) 6 (33.3)
Inflammation
0 (no foci) 2 (4.4) 1 (3.7) 1 (5.6)
1 (<2 foci per ×200) 20 (43.4) 7 (25.9) 5 (27.7)
2 (2-4 foci per ×200) 22 (47.8) 17 (63.0) 11 (61.1)
3 (>4 foci per ×200) 2 (4.4) 2 (7.4) 1 (5.6)
Ballooning
0 (none) 15 (32.6) 7 (25.9) 6 (33.3)
1 (few balloon cells) 26 (56.5) 16 (59.3) 10 (55.6)
2 (many cells) 5 (10.9) 4 (14.8) 2 (11.1)
Values are presented as number (%) or mean±standard deviation. 
BMI, body mass index; NAS, nonalcoholic fatty liver disease activity score. 
Table 2. Diagnostic performance of TE and SWE-10, SWE-5, or 
SWE-3 for the diagnosis of significant (F2-F4) and advanced 
fibrosis (F3-F4)
AUROC 95% CI P-value
Significant fibrosis
TE 0.719 0.572-0.867 0.016
SWE-10 0.787 0.646-0.927 0.002
SWE-5 0.809 0.676-0.942 0.001 
SWE-3 0.714 0.560-0.869 0.021
P-value 0.301
Advanced fibrosis
TE 0.799 0.646-0.952 <0.001
SWE-10 0.797 0.659-0.935 <0.001
SWE-5 0.809 0.684-0.933 <0.001
SWE-3 0.736 0.587-0.885 0.003
P-value 0.496
TE, transient elastography; SWE-10, p-SWE with 10 measurements; SWE-5, p-SWE 
with five measurements; SWE-3, p-SWE with three measurements; p-SWE, point 
shear-wave elastography; AUROC, area under the receiving operator characteristic 
curve; CI, confidence interval.
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P<0.001) than TE (AUROC, 0.799; 95% CI, 0.646 to 0.952; 
P<0.001), SWE-10 (AUROC, 0.797; 95% CI, 0.659 to 0.935; 
P<0.001), and SWE-3 (AUROC, 0.736; 95% CI, 0.587 to 0.885; 
P=0.003), although the differences among AUROC curves did not 
reach statistical significance (P=0.496) (Figs. 3, 4).
Optimal Cutoff for the Diagnosis of Significant and Advanced 
Fibrosis
The optimal cutoff values based on the Youden index of sensitivity 
and specificity are reported in Table 3. When using TE, an LS ≥7.9 
kPa demonstrated a sensitivity of 63.0% and a specificity of 63.2% 
Fig. 1. Receiver operating characteristic curves for liver stiffness 
measurements obtained with transient elastography (TE) and 
point shear-wave elastography (p-SWE) for the diagnosis of 
significant fibrosis (F2-F4). SWE-10, p-SWE with 10 measurements; 
SWE-5, p-SWE with five measurements; SWE-3, p-SWE with three 
measurements.
1-Specificity (%)



















Fig. 3. Receiver operating characteristic curve for liver stiffness 
measurements obtained with transient elastography (TE) and 
point shear-wave elastography (p-SWE) for the diagnosis of 
advanced fibrosis (F3-F4). SWE-10, p-SWE with 10 measurements; 
SWE-5, p-SWE with five measurements; SWE-3, p-SWE with three 
measurements.
1-Specificity (%)




















Fig. 2. Point shear-wave elastography in a 44-year-old man with significant fibrosis. 
A. Intercostal ultrasound image in the supine position shows a region of interest located under the liver capsule at a depth of 3.5 cm. B. 
Ten valid measurements are reported with a final median liver stiffness value of 8.7 kPa indicated in the lowest part of the image. A good 
interquartile range is also shown. 
B
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for the diagnosis of significant fibrosis, while an LS ≥8.5 kPa had 
a sensitivity of 77.8% and a specificity of 78.6% for the diagnosis 
of advanced fibrosis. When using the conventional SWE-10, an LS 
of ≥8.4 kPa demonstrated a sensitivity of 74.0% and a specificity 
of 73.7% for the diagnosis of significant fibrosis (Fig. 2), while an 
LS ≥9.1 kPa had a sensitivity of 72.2% and a specificity of 78.5% 
for the diagnosis of advanced fibrosis (Fig. 4). A slight increase in 
sensitivity, without a significant loss in specificity, was noted for the 
SWE-5 cutoffs of ≥7.8 kPa for the diagnosis of significant fibrosis 
and ≥8.8 kPa for the diagnosis of advanced fibrosis (sensitivity of 
77.8% with both cutoffs).
Alternative cutoffs calculated in order to achieve the highest 
sensitivity and specificity (≥90%) are presented in Table 4. When 
using TE, an alternative cutoff of 4.6 kPa increased the sensitivity of 
the diagnosis of advanced fibrosis to 94.4%, with a significant drop 
in specificity to 14.3%. Interestingly, an alternative cutoff of 7.6 
kPa for SWE-5 increased the sensitivity to 94.4%, with little drop in 
specificity (60.7%) for the diagnosis of advanced fibrosis. 
Correlations of LS Measurements with Clinical and 
Histopathological Parameters 
Table 5 shows the correlations between LS measurements measured 
with TE and p-SWE and fibrosis grade, histopathological markers of 
NASH, and selected laboratory parameters. There were statistically 
significant correlations between TE and SWE-10 (P=0.001), 
SWE-5 (P=0.001), and SWE-3 (P=0.006). Statistically significant 
correlations were likewise observed between fibrosis grade and 
TE (P<0.001), SWE-10 (P<0.001), SWE-5 (P<0.001), and SWE-3 
(P=0.005). LS measurements were significantly different in patients 
with and without diabetes using TE (P=0.006), SWE-10 (P=0.006), 
and SWE-5 (P=0.016), but not using SWE-3 (P=0.125). 
Discussion
Our study demonstrated that p-SWE provided accurate results 
for the assessment of hepatic fibrosis in patients with biopsy-
proven NAFLD, with a fair-to-good performance for the diagnosis 
of significant and advanced fibrosis. Compared to TE, there were 
Fig. 4. Point shear-wave elastography in a 69-year-old man with advanced fibrosis. 
A. Intercostal ultrasound image in the supine position shows a region of interest located under the liver capsule at a depth of 3.3 cm. B. Ten 
valid measurements are reported with a final median liver stiffness value of 18.3 kPa, as indicated in the lowest part of the image. A good 
interquartile range is also shown.
A B
Table 3. Cutoff values based on the Youden index, with sensitivity 
and specificity values, of liver stiffness measurement by TE and 
SWE-10, SWE-5, or SWE-3 for the diagnosis of significant (F2-F4) 










TE ≥7.9 63.0 63.2 63.0
SWE-10 ≥8.4 74.0 73.7 73.9
SWE-5 ≥7.8 77.8 73.4 76.1
SWE-3 ≥7.8 66.7 63.2 65.2
Advanced fibrosis
TE ≥8.5 77.8 78.6 78.3
SWE-10 ≥9.1 72.2 78.5 76.1
SWE-5 ≥8.8 77.8 75.0 76.1
SWE-3 ≥8.2 66.7 71.4 69.6
TE, transient elastography; SWE-10, p-SWE with 10 measurements; SWE-5, p-SWE 
with five measurements; SWE-3, p-SWE with three measurements; p-SWE, point 
shear-wave elastography.
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no significant differences in diagnostic performances of SWE-10, 
SWE-5, or SWE-3 for the diagnosis of both significant (P=0.301) 
and advanced (P=0.496) fibrosis, although SWE-10 and SWE-
5 had higher performance. Moreover, TE and different p-SWE 
measurements showed significant correlations with the fibrosis 
grade evaluated on biopsy specimens. Considering the widespread 
prevalence of NAFLD in the general population related to the 
increased prevalence of obesity and metabolic syndrome, our 
results may have significant relevance for the appropriate first-
line noninvasive assessment of patients with NAFLD. Indeed, the 
presence of significant and advanced fibrosis is an independent 
predictor of liver-related mortality, and has been associated with an 
increased risk of hepatocellular carcinoma, cardiovascular mortality, 
and type 2 diabetes mellitus [19]. 
Table 5. Correlations between TE, p-SWE, fibrosis grade, histopathological features, and laboratory markers
Exam TE Fibrosis NAS Steatosis Inflam. Ballooning BMI Chol. TG AST ALT
TE - 0.582a) 0.210 0.176 0.108 0.177 0.216 -0.275 -0.009 0.232 -0.082
P-value - <0.001a) 0.161 0.242 0.473 0.239 0.150 0.010 0.959 0.168 0.161
SWE-10 0.461a) 0.528a) 0.179 0.063 0.290 0.119 -0.084 -0.214 0.084 0.137 0.179
P-value 0.001a) <0.001a) 0.235 0.680 0.050 0.436 0.956 0.203 0.620 0.420 0.235
SWE-5 0.466a) 0.567a) 0.286 0.158 0.286 0.246 0.046 -0.295 0.145 -0.017 0.158
P-value 0.001a) <0.001a) 0.054 0.294 0.054 0.099 0.769 0.077 0.402 0.922 0.294
SWE-3 0.403a) 0.404a) 0.126 0.075 0.079 0.157 0.015 -0.182 -0.083 -0.002 0.075
P-value 0.006a) 0.005a) 0.403 0.622 0.600 0.298 0.924 0.282 0.627 0.993 0.622
Numbers represent the Spearman rank correlation coefficient (rho). 
TE, transient elastography; p-SWE, point shear-wave elastography; NAS, nonalcoholic fatty liver disease activity score; Inflam, inflammation; BMI, body mass index; Chol., 
cholesterol; TG, triglycerides; AST, aspartate transaminase; ALT, alanine transaminase; SWE-10, p-SWE with 10 measurements; SWE-5, p-SWE with five measurements; SWE-3, 
p-SWE with three measurements.
a)Statistically significant values (P<0.01 due to multiple comparisons). 
Table 4. Alternative cutoffs calculated in order to achieve high sensitivity or specificity (≥90%) of liver stiffness measurements by TE 
and SWE-10, SWE-5, or SWE-3 for the diagnosis of significant (F2-F4) and advanced fibrosis (F3-F4)
Exam Aim Cutoff (kPa) Sensitivity (%) Specificity (%)
Significant fibrosis
TE Sensitivity ≥90% 4.8 92.6 26.3
Specificity ≥90% 11.1 44.4 94.7
SWE-10 Sensitivity ≥90% 5.5 92.6 10.5
Specificity ≥90% 9.3 59.3 94.7
SWE-5 Sensitivity ≥90% 6.9 92.6 57.9
Specificity ≥90% 9.9 48.2 94.7
SWE-3 Sensitivity ≥90% 5.3 92.6 5.26
Specificity ≥90% 13.0 22.2 94.7
Advanced fibrosis
TE Sensitivity ≥90% 4.6 94.4 14.3
Specificity ≥90% 11.1 61.1 92.9
SWE-10 Sensitivity ≥90% 6.9 94.4 50.0
Specificity ≥90% 12.5 33.3 92.9
SWE-5 Sensitivity ≥90% 7.6 94.4 60.7
Specificity ≥90% 13.8 22.2 92.9
SWE-3 Sensitivity ≥90% 6.5 94.4 42.9
Specificity ≥90% 14.2 22.2 92.9
TE, transient elastography; SWE-10, p-SWE with 10 measurements; SWE-5, p-SWE with five measurements; SWE-3, p-SWE with three measurements; p-SWE, point shear-wave 
elastography.
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Limited literature exists comparing different methods for LS 
measurements in the same study population affected by NAFLD, 
especially in comparison with biopsy results [12,17,20,21]. Our 
results are concordant with those of Furlan et al. [20], who reported 
comparable diagnostic accuracy of SWE to conventional TE for the 
identification of significant and advanced fibrosis in NAFLD patients. 
In our study, the optimal cutoffs of ≥8.4 kPa and ≥9.1 kPa obtained 
by SWE-10 provided a sensitivity of 74.0% and a specificity of 
73.7% for the diagnosis of significant fibrosis, and a sensitivity of 
72.2% and a specificity of 78.5% for the diagnosis of advanced 
fibrosis, respectively. This evidence supports the use of p-SWE in 
clinical practice as a valuable alternative noninvasive method for 
the quantification of LS and a potential alternative to liver biopsy 
for the staging and follow-up of patients with NAFLD. SWE may 
have advantages over TE in patients with ascites or obesity, and 
may enable a simultaneous evaluation of focal liver lesions and LS 
measurements in patients undergoing surveillance for NAFLD [6]. 
Moreover, our study assessed the performance of the p-SWE 
technique with fewer measurements. In agreement with other 
recent evidence evaluating cohorts with different etiologies of 
chronic liver disease, we observed that SWE-5 provided the highest 
diagnostic performance (AUROC), sensitivity, and specificity for both 
significant (0.809, 77.8%, and 73.4%, respectively) and advanced 
fibrosis (0.809, 77.8%, and 75.0%, respectively) with respect to 
SWE-10 and for significant fibrosis with respect to TE, even if the 
differences were not statistically significant [22,23]. Interestingly, 
when exploring alternative cutoffs for maximizing sensitivity and 
specificity, SWE-5 with a cutoff of ≥7.6 kPa yielded an increase in 
sensitivity to 94.4%, with only a slight drop in specificity (60.7%) 
for the diagnosis of advanced fibrosis. In contrast, SWE-3 showed 
the lowest performance (AUROC, sensitivity, and specificity) for both 
significant (0.714, 66.7%, and 63.2%, respectively) and advanced 
fibrosis (0.736, 66.7%, and 71.4%, respectively). Although current 
guidelines still recommend a minimum of 10 valid measurements 
for the appropriate p-SWE examinations, conducting an evaluation 
with five valid LS measurements may potentially save time during 
examinations in clinical practice, without compromising the 
diagnostic performance for the assessment of hepatic fibrosis [14].
In our study, LS measurements by TE and p-SWE showed 
significant correlations with fibrosis grade, while no correlations 
were observed for BMI, histopathological markers of NASH, or 
laboratory results. However, in a non-negligible proportion of 
patients (17.8% of the initial cohort), LS measurements by p-SWE 
failed. In particular, patients with failed p-SWE more frequently had 
advanced fibrosis (90.0% vs. 39.2%, P=0.006), and also had higher 
BMI (mean, 33.7±4.9 kg/m2; P=0.011) and higher TE measurements 
(mean, 28.9±25.4 kPa; P<0.001) than patients with valid LS 
measurements. Cassinotto et al. [12], along with other evidence, 
also reported fewer reliable results in patients with a BMI ≥30 kg/m2 and 
a waist circumference ≥102 cm [16,24]. We speculate that, in our 
study population, this non-negligible percentage of failed p-SWE 
could be related to US equipment technology. Of note, the US 
equipment is undergoing constant updates, and the latest version 
deems the results to be reliable when the RMI is ≥0.4 instead of 
the previously suggested value of ≥0.6. This technical aspect could 
potentially decrease the percentages of failed p-SWE measurements, 
and applying this cutoff would have allowed us to include many 
more patients in our study.
It should also be noted that, on the basis of the current literature, 
each ultrasound equipment is different from the others, with 
particular reference to quantitative evaluation and optimal SWE 
cutoff values to classify significant and advanced liver fibrosis, which 
are specific for each ultrasound machine. Indeed, different software 
methods can be used to measure shear wave arrival time and speed 
[25]. This could be considered a limitation of p-SWE, since a reliable 
follow-up should always be performed in the same patient using the 
same US machine. In our study, according to EFSUMB guidelines, we 
evaluated all patients using the same US equipment by the same 
manufacturer; as such, we report our experience with this specific 
US equipment. Therefore, cutoff values are different for other US 
machines, even if the p-SWE technique has been well-known 
for some years. It should be also noted that an unquestionable 
advantage of TE with respect to p-SWE is the capability to quantify 
liver fatty content by using the controlled attenuation parameter 
(CAP), which measures ultrasound beam attenuation (a parameter 
directly related to the amount of steatosis), and enables the 
stratification of each patient in a different stage (no steatosis; 
mild, moderate, or severe steatosis) with a robust correlation with 
biopsy results. CAP measurements are important for the TE LS 
evaluation since LS can be overestimated in patients with high CAP 
values, which has led to the adjustment of TE cutoff values and 
the development of new ultrasound software [26-28]. Moreover, 
before performing SWE, confounding factors should be assessed 
to prevent the overestimation of LS measurements; patients with 
liver inflammation (AST and/or ALT elevation >5 times the normal 
limits), obstructive cholestasis, liver congestion, acute hepatitis, and 
infiltrative liver diseases should be excluded before measuring LS, as 
recommended by EFSUMB guidelines [14].
Our study has multiple limitations that need to be acknowledged. 
First, our study population was limited by the relatively small 
number of prospectively-enrolled patients in a single Institution 
related to our selection criteria and the RMI cutoff values 
considered to indicate reliable measurements. The final number of 
included patients and the exclusion of patients with failed SWE 
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measurements may have limited the evaluation of differences in 
diagnostic performance between TE and p-SWE with different 
measurements. However, all the included subjects underwent 
histopathological examinations with percutaneous liver biopsy 
within 1 month and underwent laboratory tests on the same day 
of TE and p-SWE evaluation. Second, p-SWE was performed by a 
single radiologist, therefore, inter-reader agreement could not be 
evaluated. Other studies have already investigated the inter- and 
intra-reader reproducibility of SWE techniques [29]. Finally, our 
population included only four patients lacking fibrosis (F0) on biopsy 
specimens.
In conclusion, TE and p-SWE had similar fair-to-good diagnostic 
performance for the diagnosis of biopsy-proven significant and 
advanced fibrosis in patients with NAFLD. 
ORCID: Adele Taibbi: https://orcid.org/0000-0001-6442-744X; Salvatore Petta: https://
orcid.org/0000-0002-0822-9673; Domenica Matranga: https://orcid.org/0000-0002-
2466-937X; Giovanni Caruana: https://orcid.org/0000-0002-0239-5005; Roberto 
Cannella: https://orcid.org/0000-0002-3808-0785; Vito Di Marco: https://orcid.org/0000-
0001-6397-4206; Massimo Midiri: https://orcid.org/0000-0003-1824-7549; Tommaso 
Vincenzo Bartolotta: https://orcid.org/0000-0002-8808-379X 
Author Contributions
Conceptualization: Taibbi A, Petta S, Di Marco V, Midiri M, Bartolotta 
TV. Data acquisition: Taibbi A, Petta S, Caruana G, Busè G, Bartolotta 
TV. Data analysis or interpretation: Taibbi A, Matranga D, Caruana 
G, Cannella R, Bartolotta TV. Drafting of the manuscript: Taibbi A, 
Cannella R. Critical revision of the manuscript: Taibbi A, Petta S, 
Matranga D, Caruana G, Cannella R, Busè G, Di Marco V, Midiri M, 
Bartolotta TV. Approval of the final version of the manuscript: all 
authors. 
Conflict of Interest
Tommaso V incenzo Bar to lot ta  serves  as  Ed i tor  for  the 
Ultrasonography, but has no role in the decision to publish this 
article. All remaining authors have declared no conflicts of interest. 
References
 1. Taibbi A, Picone D, Midiri M, La Grutta L, Bartolotta TV. Diffuse liver 
diseases: role of imaging. Semin Ultrasound CT MR 2018;39:193-
205.
 2. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. 
JAMA 2015;313:2263-2273.
 3. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment 
of liver disease in patients with nonalcoholic fatty liver disease. 
Gastroenterology 2019;156:1264-1281.
 4. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et 
al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic 
steatohepatitis among a largely middle-aged population utilizing 
ultrasound and liver biopsy: a prospective study. Gastroenterology 
2011;140:124-131.
 5. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev 
Gastroenterol Hepatol 2013;10:686-690.
 6. Petta S, Maida M, Macaluso FS, Di Marco V, Camma C, Cabibi D, et 
al. The severity of steatosis influences liver stiffness measurement 
in patients with nonalcoholic fatty liver disease. Hepatology 
2015;62:1101-1110.
 7. Lee SM, Kim MJ, Yoon JH, Hong W, Ha HI, Lee K, et al. Comparison 
of point and 2-dimensional shear wave elastography for the 
evaluation of liver fibrosis. Ultrasonography 2020;39:288-297.
 8. Bamber J, Cosgrove D, Dietrich CF, Fromageau J, Bojunga J, 
Calliada F, et al. EFSUMB guidelines and recommendations on the 
clinical use of ultrasound elastography. Part 1: Basic principles and 
technology. Ultraschall Med 2013;34:169-184.
 9. Nierhoff J, Chavez Ortiz AA, Herrmann E, Zeuzem S, Friedrich-Rust 
M. The efficiency of acoustic radiation force impulse imaging for the 
staging of liver fibrosis: a meta-analysis. Eur Radiol 2013;23:3040-
3053.
10. Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C, et 
al. Accuracy of real-time shear wave elastography for assessing 
liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 
2012;56:2125-2133.
11. Cassinotto C, Lapuyade B, Mouries A, Hiriart JB, Vergniol J, Gaye 
D, et al. Non-invasive assessment of liver fibrosis with impulse 
elastography: comparison of supersonic shear imaging with ARFI 
and FibroScan®. J Hepatol 2014;61:550-557.
12. Cassinotto C, Boursier J, de Ledinghen V, Lebigot J, Lapuyade B, 
Cales P, et al. Liver stiffness in nonalcoholic fatty liver disease: a 
comparison of supersonic shear imaging, FibroScan, and ARFI with 
liver biopsy. Hepatology 2016;63:1817-1827.
13. Liu H, Fu J, Hong R, Liu L, Li F. Acoustic radiation force impulse 
elastography for the non-invasive evaluation of hepatic fibrosis in 
non-alcoholic fatty liver disease patients: a systematic review and 
meta-analysis. PLoS One 2015;10:e0127782.
14. Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, 
et al. EFSUMB guidelines and recommendations on the clinical 
use of liver ultrasound elastography, update 2017 (long version). 
Ultraschall Med 2017;38:e16-e47.
15. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, 
Lebail B, et al. Determination of reliability criteria for liver stiffness 
evaluation by transient elastography. Hepatology 2013;57:1182-
1191.
16. Kang HJ, Lee JY, Lee KB, Joo I, Suh KS, Lee HK, et al. Addition of 
reliability measurement index to point shear wave elastography: 
prospect ive val idat ion v ia diagnost ic  performance and 
Adele Taibbi, et al.
416  Ultrasonography 40(3), July 2021 e-ultrasonography.org
reproducibility. Ultrasound Med Biol 2019;45:1594-1602.
17. Leong WL, Lai LL, Nik Mustapha NR, Vijayananthan A, Rahmat 
K, Mahadeva S, et al. Comparing point shear wave elastography 
(ElastPQ) and transient elastography for diagnosis of fibrosis 
stage in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 
2020;35:135-141.
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, 
Cummings OW, et al. Design and validation of a histological 
scoring system for nonalcoholic fatty liver disease. Hepatology 
2005;41:1313-1321.
19. Vernon G, Baranova A, Younossi ZM. Systematic review: the 
epidemiology and natural history of non-alcoholic fatty liver disease 
and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 
2011;34:274-285.
20. Furlan A, Tublin ME, Yu L, Chopra KB, Lippello A, Behari J. 
Comparison of 2D shear wave elastography, transient elastography, 
and MR elastography for the diagnosis of fibrosis in patients 
with nonalcoholic fatty liver disease. AJR Am J Roentgenol 
2020;214:W20-W26.
21. Jiang W, Huang S, Teng H, Wang P, Wu M, Zhou X, et al. 
Diagnostic accuracy of point shear wave elastography and 
transient elastography for staging hepatic fibrosis in patients 
with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open 
2018;8:e021787.
22. Roccarina D, Iogna Prat L, Buzzetti E, Guerrero Misas M, Arico FM, 
Saffioti F, et al. Establishing reliability criteria for liver ElastPQ shear 
wave elastography (ElastPQ-SWE): comparison between 10, 5 and 
3 measurements. Ultraschall Med 2021;42:204-213.
23. Fang C, Jaffer OS, Yusuf GT, Konstantatou E, Quinlan DJ, Agarwal K, 
et al. Reducing the number of measurements in liver point shear-
wave elastography: factors that influence the number and reliability 
of measurements in assessment of liver fibrosis in clinical practice. 
Radiology 2018;287:844-852.
24. Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. 
Transient elastography (FibroScan(®)) with controlled attenuation 
parameter in the assessment of liver steatosis and fibrosis in 
patients with nonalcoholic fatty liver disease: where do we stand? 
World J Gastroenterol 2016;22:7236-7251.
25. Sugimoto K, Moriyasu F, Oshiro H, Takeuchi H, Yoshimasu Y, Kasai Y, 
et al. Clinical utilization of shear wave dispersion imaging in diffuse 
liver disease. Ultrasonography 2020;39:3-10.
26. Petta S, Wong VW, Camma C, Hiriart JB, Wong GL, Marra F, et al. 
Improved noninvasive prediction of liver fibrosis by liver stiffness 
measurement in patients with nonalcoholic fatty liver disease 
accounting for controlled attenuation parameter values. Hepatology 
2017;65:1145-1155.
27. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled 
attenuation parameter (CAP): a novel tool for the non-invasive 
evaluation of steatosis using Fibroscan. Clin Res Hepatol 
Gastroenterol 2012;36:13-20.
28. Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques 
for the diagnosis of liver steatosis. World J Gastroenterol 
2019;25:6053-6062.
29. Yoo J, Lee JM, Joo I, Yoon JH. Assessment of liver fibrosis using 
2-dimensional shear wave elastography: a prospective study of 
intra- and inter-observer repeatability and comparison with point 
shear wave elastography. Ultrasonography 2020;39:52-59.
